Novo Nordisk Publishes 2025 Annual Report

An update from Novo Nordisk ( (NVO) ) is now available.

On 4 February 2026, Novo Nordisk A/S published its annual report for the 2025 financial year, making the document available to investors in digital and iXBRL formats via its website. The filing underscores the company’s continued transparency and regulatory compliance as a foreign private issuer in the United States, providing shareholders and analysts with a detailed basis for assessing Novo Nordisk’s recent performance and outlook in the global healthcare and chronic disease markets.

The most recent analyst rating on (NVO) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.

The score is driven primarily by strong underlying profitability and solid cash generation, but it is held back by weak price trend/technical setup and a cautious 2026 outlook with pricing and policy-driven headwinds. Valuation and dividend yield provide partial support.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focused on defeating serious chronic diseases built on its heritage in diabetes care. The company pioneers scientific breakthroughs, expands access to its medicines, and works on prevention and potential cures, employing about 68,800 people in 80 countries and marketing its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen and its American depositary receipts trade on the New York Stock Exchange.

Average Trading Volume: 21,498,162

Technical Sentiment Signal: Sell

Current Market Cap: $213.7B

Find detailed analytics on NVO stock on TipRanks’ Stock Analysis page.